Blocking NO synthesis: how, where and why?

Vallance, P. and Leiper, J. (2002) Blocking NO synthesis: how, where and why? Nature Reviews Drug Discovery, 1(12), pp. 939-950. (doi: 10.1038/nrd960) (PMID:12461516)

Full text not currently available from Enlighten.


Nitric oxide (NO) is a key physiological mediator, and the association of disordered NO generation with many pathological conditions has led to much interest in pharmacologically modulating NO levels. However, the wide range of processes in which NO has been implicated, and the fact that increases or decreases in NO levels might be therapeutically desirable depending on the condition or even at different stages of the same condition, pose considerable challenges for drug development. Here, we focus on the rationale and potential for approaches that reduce NO synthesis, which have led to the development of several compounds that will shortly be entering clinical trials.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Leiper, Professor James
Authors: Vallance, P., and Leiper, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Nature Reviews Drug Discovery
Publisher:Nature Publishing Group
ISSN (Online):1474-1784

University Staff: Request a correction | Enlighten Editors: Update this record